Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

Choose NJ’s RFP Watch

Choose New Jersey’s RFP Watch provides up-to-date information on business opportunities throughout the Garden State at a cost that is affordable for all companies – with a place of business in New Jersey – large and small.

To learn more click here

Research

National Organizations Support Outreach Efforts for NIH’s ‘All of Us’ Research Program

Bethesda, MD, November 29, 2017 — Fourteen national community groups and health care provider associations have partnered with the All of Us Research Program, part of the National Institutes of Health, to help raise awareness about the program — an effort to engage 1 million or more volunteers across the country to build one of the largest, most diverse datasets of its kind for health research.

This inaugural group of organizations will receive a combined $1 million to help educate their communities about the benefits of participation in this landmark project to accelerate breakthroughs in precision medicine.

“We want to build long-term relationships with our participants based on transparency and trust. These organizations will help us in that effort,” said Eric Dishman, director of the All of Us Research Program at NIH. Continue reading

Rutgers Names David Kimball as VP for Innovation and Research Commercialization of Office of Research and Economic Development

Dr. David Kimball

New Brunswick, NJ, November 25, 2017 — Rutgers University on October 23 announced the appointment of David Kimball, Ph.D., as vice president for innovation and research commercialization of the Office of Research and Economic Development (ORED).

Most recently, Dr. Kimball led translational science and research commercialization as associate vice president in ORED.

“I am delighted to announce David’s promotion to Vice President of Innovation and Research Commercialization,” said Christopher J. Molloy, Ph.D., R.Ph., Senior Vice President for Research and Economic Development at Rutgers University. Continue reading

Hill Fight Erupts Over GOP’s Proposed Roll-Back of Tax Credit for ‘Orphan’ Disease Drugs

Washington, DC, November 21, 2017 — Peter Sullivan reports in The Hill that Republicans are seeking to roll back a tax credit for drugs that treat rare diseases, alarming patient groups who fear the move would slow the development of new treatments.

The so-called orphan drug tax credit would be repealed in the tax-reform bill that passed the House last week. Patient groups are lobbying to preserve the credit, as are some drug companies.

The credit, first enacted in 1983, is intended to spur the development treatments for rare, or “orphan,” diseases that affect fewer than 200,000 people. Continue reading

FDA Announces Comprehensive Regenerative Medicine Policy Framework

Washington, DC, November 20, 2017 — The U.S. Food and Drug Administration (FDA) on November 16 announced a comprehensive policy framework for the development and oversight of regenerative medicine products, including novel cellular therapies.

The framework – outlined in a suite of four guidance documents – builds upon the FDA’s existing risk-based regulatory approach to more clearly describe what products are regulated as drugs, devices, and/or biological products.

Further, two of the guidance documents propose an efficient, science-based process for helping to ensure the safety and effectiveness of these therapies, while supporting development in this area. Continue reading

Bill Gates Investing $50 Million to Help Alzheimer’s Research — And It’s Personal

Bill Gates

Seattle, WA, November 16, 2017 — Lindsey Bever reports in The Washington Post that Bill Gates is personally investing $50 million to help fund research to find a treatment for Alzheimer’s disease, a type of dementia Gates says has struck members of his own family.

There is no cure for Alzheimer’s, which destroys memory and other mental processes, so Gates said he is investing his own money in the Dementia Discovery Fund, a private-public partnership to search for a solution.

“It’s a terrible disease that devastates both those who have it and their loved ones,” the philanthropist wrote on November 13 on his blog. Continue reading

Rutgers-Led Research May Lead to New Treatments for Neurodegenerative Diseases and Nerve Injuries

Robert O’Hagan

New Brunswick, NJ, November 13, 2017 — Todd B. Bates reports that inside cells, protein “motors” act like trucks on tiny cellular highways to deliver life-sustaining cargoes.

Now a team led by Rutgers University–New Brunswick researchers has discovered how cells deploy enzymes to place traffic control and “roadway under construction” signs along cellular highways.

“To stay alive and function, every cell in our body needs to transport cargoes to the place they’re needed inside the cell, in the right amount and at the right time,” said Robert O’Hagan, lead author of a new study and assistant research professor in the Human Genetics Institute of New Jersey and the Department of Genetics at Rutgers University–New Brunswick. Continue reading

PhRMA ‘Pipeline’ Report: 74 Percent of Medicines in Development Have Potential to Be First-in-Class Treatments

Washington, DC, November 11, 2017 — Seventy-four percent of medicines in clinical development around the world are potentially first-in-class medicines, meaning they use a completely new approach to fighting a disease, according to a September report by The Analysis Group, Inc. commissioned by the Pharmaceutical Research and Manufacturers of America (PhRMA).

“The Biopharmaceutical Pipeline: Innovative Therapies in Clinical Development” report examines the global state of the drug development pipeline and provides insights into new approaches biopharmaceutical researchers are pursuing.

The pipeline report, which updates a previous analysis, highlights new treatment approaches such as cell therapy and gene therapy, as well as DNA or RNA therapeutics and conjugated monoclonal antibodies. Continue reading

Rutgers’ Amarel Technology Helps Research Community Solve Enormous Calculations and Variables; Allows Collating Big Data with Advanced Computing

Piscataway, NJ, November 7, 2017 — Arthur Augustyn reports in NJBIZ that as companies get larger, so do their challenges.  For big data problems, the difficulty isn’t finding a solution but understanding the scale of an issue.

Computers have been an integral part of simplifying company problems and finding solutions at faster rates than individuals.  But as the problems of businesses get large and more complex, computers also need to beef up.

Rutgers University’s Office of Advanced Research Computing rolled out its most advanced technology yet in July.  “Amarel,” is a computing system meant to assist the research community with tackling problems that require a massive amount of calculations and variables. Continue reading

R&D Council of NJ Presents 2017 Edison Patent Awards and Special Recognitions Honors

Jersey City, NJ, November 3, 2017 ― The Research & Development Council of New Jersey presented its 2017 Annual Edison Patent Awards on November 2 at the Liberty Science Center in Jersey City, NJ.

The 2017 Edison Patent Award winners were:

  • Biomaterials: Rutgers, The State University of New Jersey
  • Biomedical: New Jersey Institute of Technology (NJIT)
  • Energy: Siemens Energy
  • Environmental: BASF
  • Imaging Systems: Princeton Plasma Physical Laboratory
  • Industrial Process: ExxonMobil
  • Information Technology: Avaya
  • Instrumentation: Stevens Institute of Technology
  • Materials: Honeywell
  • Medical: Ethicon
  • Pharmaceutical: Lexicon Pharmaceuticals
  • Pharmaceutical: Merck & Co., Inc.
  • Technology Transfer: Princeton University
  • Telecommunications: Nokia Bell Labs

Continue reading

Dr. Jeetu Eswaraka Named Assistant Vice President for Comparative Medicine Resources at Rutgers Office of Research and Economic Development

Dr. Jeetendra (Jeetu) Eswaraka

New Brunswick, NJ, October 26, 2017 — Jeetendra (Jeetu) Eswaraka, DVM, Ph.D., DACLAM, who joined Rutgers University’s Office of Research and Economic Development (ORED) earlier this month as Assistant Vice President for Comparative Medicine Resources, brings a decade and a half of experience leading lab animal research programs in the biopharmaceutical industry.

“I am excited to welcome Jeetu to ORED and Rutgers, and look forward to strengthening and streamlining our operations to be of greater service to the Rutgers research community,” said Christopher J. Molloy, Ph.D., R.Ph., Senior Vice President for Research and Economic Development at Rutgers University. Continue reading